rais quarter path upsid
remain challeng increas tp
solid quarter drive target price increas question mid-term
outlook remain report strong top-line beat quarter driven
combin factor fx price volum
drove quarter bottom line beat combin lower expens
rais revenu guidanc driven favor segment
payer mix along fx movement fx move increas ms
 expect year slightli off-set lower tax rate
guidanc boost overal non-gaap ep
guidanc humalog trulic
largest beat quarter driven price volum respect
howev maintain view concern around success
product mid-long term expect humalog face
pressur biosimilar admelog follow reimburs negoti
trulic face pressur victoza ozemp short term
addit possibl oral semaglutid mid-long term also believ
risk/reward head upcom catalyst includ baricitinib
pdufa earli june rewind cv outcom data earli skew
toward downsid target price
blend dcf rel valuat maintain
under-perform rate given challeng see face especi
diabet franchis main risk call stronger expect
commerci execut especi key diabet oncolog product
disappoint key competitor
summari model chang rais humalog trulic alimta sale
lower forteo taltz sale reflect updat market price
volum dynam sale compound-annual-growth-rate in-lin
guidanc see much risk downsid
upsid upcom catalyst go way
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
follow-up manag
opportun speak member team follow confer
call gain addit clariti dynam around certain product
well bake updat expect around fy
summar compani answer question
driver sale growth
still expect driven new product includ trulic taltz basaglar
jardianc verzenio cyramza olumi lartruvo
keep eye alimta prescript trend expect declin due
competit i-o get boost result
forteo weak quarter given signific stock result burn
forteo
jardianc benefit
us price growth
expect
element expect put intial guidanc
slow growth medicaid channel
saw benefit come
trend util less expect higher rebat
channel higher util lower rebat
didnt off-set increas list price much
major structur chang expect dynam last
coupl quarter
averag list price increas quarter low seen
would launch drug us dose approv
feel strongli get approv work fda clear approv
path potenti differ indic vote
jardianc type diabet
high risk higher bar
scientif think interest want explor dont think larg
commerci opportun regardless data show
much cost come anim health vs pharma
elanco qualit lower gross margin percentag
elanco sg percentag sale close pharma percentag
sale much lower
much pharma manufactur connect elanco
almost none strict human pharma side made switch year ago
clarifi cfo posit new
upgrad posit best way put
mani scenario help addit expertis execut
whatev decis may
time-frame make decis ah
expect announc decis juli earn call
come intern decis yet need present board etc
feel room one decent-s deal regulatori issu may
make decis want posit execut decis
sale
sale
sale
total incom expens
provis incom tax
galcanezumab migrain headach
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
price apr rate under-perform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
abemaciclib olaratumab compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale trulic
olaratumab compar current base case assumpt
grey sky valuat base dcf driven wacc
compani mention price
